PMID- 32472766
OWN - NLM
STAT- MEDLINE
DCOM- 20210607
LR  - 20220222
IS  - 2768-6698 (Electronic)
IS  - 2768-6698 (Linking)
VI  - 25
IP  - 11
DP  - 2020 Jun 1
TI  - New Insights for nicotinamide: Metabolic disease, autophagy, and mTOR.
PG  - 1925-1973
AB  - Metabolic disorders, such as diabetes mellitus (DM), are increasingly becoming 
      significant risk factors for the health of the global population and consume 
      substantial portions of the gross domestic product of all nations. Although 
      conventional therapies that include early diagnosis, nutritional modification of 
      diet, and pharmacological treatments may limit disease progression, tight serum 
      glucose control cannot prevent the onset of future disease complications. With 
      these concerns, novel strategies for the treatment of metabolic disorders that 
      involve the vitamin nicotinamide, the mechanistic target of rapamycin (mTOR), 
      mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), AMP activated protein kinase 
      (AMPK), and the cellular pathways of autophagy and apoptosis offer exceptional 
      promise to provide new avenues of treatment. Oversight of these pathways can 
      promote cellular energy homeostasis, maintain mitochondrial function, improve 
      glucose utilization, and preserve pancreatic beta-cell function. Yet, the 
      interplay among mTOR, AMPK, and autophagy pathways can be complex and affect 
      desired clinical outcomes, necessitating further investigations to provide 
      efficacious treatment strategies for metabolic dysfunction and DM.
FAU - Maiese, Kenneth
AU  - Maiese K
AD  - Cellular and Molecular Signaling, New York, New York 10022, wntin75@yahoo.com.
LA  - eng
GR  - R01 NS053946/NS/NINDS NIH HHS/United States
GR  - RA/ARRA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200601
PL  - Singapore
TA  - Front Biosci (Landmark Ed)
JT  - Frontiers in bioscience (Landmark edition)
JID - 101612996
RN  - 25X51I8RD4 (Niacinamide)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
SB  - IM
MH  - AMP-Activated Protein Kinases/metabolism
MH  - Animals
MH  - Apoptosis/physiology
MH  - Autophagy/*physiology
MH  - Humans
MH  - Metabolic Diseases/*metabolism
MH  - Models, Biological
MH  - Niacinamide/*metabolism
MH  - Signal Transduction/*physiology
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC7265993
MID - NIHMS1576656
EDAT- 2020/05/31 06:00
MHDA- 2021/06/08 06:00
PMCR- 2020/06/02
CRDT- 2020/05/31 06:00
PHST- 2020/05/31 06:00 [entrez]
PHST- 2020/05/31 06:00 [pubmed]
PHST- 2021/06/08 06:00 [medline]
PHST- 2020/06/02 00:00 [pmc-release]
AID - 4886 [pii]
AID - 10.2741/4886 [doi]
PST - epublish
SO  - Front Biosci (Landmark Ed). 2020 Jun 1;25(11):1925-1973. doi: 10.2741/4886.